🇺🇸 FDA
Pipeline program

Doxazosin extended release

2-P50-DA018197-DoxMeth

Phase 2 small_molecule completed

Quick answer

Doxazosin extended release for Methamphetamine or Cocaine Dependence is a Phase 2 program (small_molecule) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
BRIGHT MINDS BIOSCIENCES INC.
Indication
Methamphetamine or Cocaine Dependence
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials